Alcon Inc

ALC: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$52.00GkfwjhPlcpppcm

Alcon Posts Steady Q4 With Signs of Strong Surgical Demand on the Horizon

Narrow-moat Alcon posted steady fourth-quarter results, with solid top-line growth augmented by new products, and fairly robust margins in light of continued supply challenges. We see some room for a rebound through 2023-24, but this depends on procedure volumes and supply cost inflation. We don't expect any major changes to our $53 fair value estimate based on its earnings.

Sponsor Center